IP Library Granted Patent US 10,836,746
Granted Patent B2
US 10,836,746 · App. 16/275,605 · Granted Nov 17, 2020

Therapeutic compounds

Inventors: Gediminas Brizgys (San Carlos, CA); Eda Canales (San Mateo, CA); Chienhung Chou (Dublin, CA); Michael Graupe (Pacifica, CA); Jiayao Li (Foster City, CA); Roland D. Saito (San Mateo, CA); Scott D. Schroeder (Union City, CA); Winston C. Tse (Redwood City, CA); Qiaoyin Wu (Foster City, CA); Jennifer R. Zhang (Union City, CA)
Assignee: Gilead Sciences, Inc.
C07D401/14A61P31/18C07D405/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,836,746
App. No.
16/275,605
Granted
Nov 17, 2020
Kind
B2
Abstract

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Claims (67)

1. A compound of formula I:

wherein

A is 3-6 membered carbocycle;

n is 0, 1, or 2;

m is 0, 1, or 2;

R 1 is 5-12 membered heteroaryl or 5-12 membered heterocycle, wherein any 5-12 membered heteroaryl or 5-12 membered heterocycle of R 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1 groups, wherein the Z 1 groups are the same or different;

each Z 1 is independently (C 1 -C 6 )alkyl; (C 3 -C 7 )carbocycle; halogen, or —CN, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen; (C 3 -C 7 )carbocycle; —OH, or —CN;

R 2 is hydrogen, halogen, —OH, or —CN;

R 3 is (C 1 -C 6 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 6 )alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms;

R 4 is

R 5 is hydrogen or halogen; and

R 6 is (C 1 -C 3 )alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of formula Ia:

wherein:

n is 0, 1, or 2;

m is 0 or 1;

R 1 is 5-9 membered heteroaryl or 5-9 membered heterocycle, wherein any 5-9 membered heteroaryl or 5-9 membered heterocycle of R 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1 groups, wherein the Z 1 groups are the same or different;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen or iodide;

R 3 is (C 1 -C 2 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 halogen atoms;

R 5 is hydrogen, chorine, or fluorine; and

R 6 is (C 1 -C 3 )alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or 2;

m is 0 or 1;

R 1 is 5-9 membered heteroaryl that is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1 groups, wherein the Z 1 groups are the same or different;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen or iodide;

R 3 is (C 1 -C 2 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;

R 5 is hydrogen, chorine, or fluorine; and

R 6 is methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or 2;

m is 0 or 1;

R 1 is 5-9 membered heteroaryl that is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1 groups, wherein the Z 1 groups are the same or different;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen;

R 3 is (C 1 -C 2 )alkyl or 4-membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;

R 5 is hydrogen, chorine, or fluorine; and

R 6 methyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib:

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of formula Ic:

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z 1 is (C 1 -C 6 )alkyl substituted with 2 or 3 halogen atoms, a cyclopropyl group, or halogen.

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z 1 is —CHF 2 , —CF 3 , or halogen.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen or iodide.

19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is (C 1 -C 3 )alkyl or a 4-membered heterocycle, wherein the (C 1 -C 3 )alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms.

20. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is methyl, —CH 2 CHF 2 , —CH 2 CF 3 , or

21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, chloride, or fluoride.

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1 and R 6 is (C 1 -C 3 )alkyl.

23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1 and R 6 is methyl.

24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is

25. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

26. A method for treating a HIV infection in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2019
From: LI, JIAYAO
To: GILEAD SCIENCES, INC.
Reel/Frame 048689/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2019
From: BRIZGYS, GEDIMINAS; CANALES, EDA; CHOU, CHIENHUNG; GRAUPE, MICHAEL; SAITO, ROLAND D.; SCHROEDER, SCOTT D.; WU, QIAOYIN; ZHANG, JENNIFER R.; TSE, WINSTON C.
To: GILEAD SCIENCES, INC.
Reel/Frame 048460/0383 →
Continuity (2)
Provisional Application 62630955 · Feb 15, 2018
Related Publication 20190345136A1 · Nov 14, 2019
Cited By (5)
US 12,187,753 US 12,404,262 US 12,492,189 US 12,594,267 US 12,636,279